{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:20:26Z","timestamp":1785154826602,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As many as 2.4 million Americans are affected by chronic Hepatitis C Virus (HCV) in the United States.In 2018, the estimated number of adults with a history of HCV infection in San Diego County was 55,354 (95% CI: 25,411\u201393,329). This corresponded to a seroprevalence of 2.1% (95% CI: 2.1\u20133.4%). One-third of infections were among PWID. Published research has demonstrated that direct-acting antivirals (DAAs) have high efficacy and can now be used by primary care providers to treat HCV. In addition, limited evidence exists to support the effectiveness of simplified algorithms in clinical trial and real-world settings. Even with expanded access to HCV treatment in primary care settings, there are still groups, especially people who inject drugs (PWID) and people experiencing homelessness, who experience treatment disparities due to access and treatment barriers. The current study extends the simplified algorithm with a streetside \u2018one-stop-shop\u2019 approach with integrated care (including the offer of buprenorphine prescriptions and abscess care) using a mobile clinic situated adjacent to a syringe service program serving many homeless populations. Rates of HCV treatment initiation and retention will be compared between patients offered HCV care in a mobile clinic adjacent to a syringe services program (SSP) and homeless encampment versus those who are linked to a community clinic\u2019s current practice of usual care, which includes comprehensive patient navigation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A quasi-experimental, prospective, interventional, comparative effectiveness trial with allocation of approximately 200 patients who inject drugs and have chronic HCV to the \"simplified care\" pathway (intervention group) or the \"usual care\" pathway (control group). Block randomization will be performed with a 1:1 randomization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Previous research has demonstrated acceptable outcomes for patients treated using simplified algorithms for DAAs and point-of-care testing in mobile medical clinics; however, there are opportunities to explore how these new, innovative systems of care impact treatment initiation rates or other HCV care cascade outcomes among PWID.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>We have registered our study with ClinicalTrials.gov, a resource of the United States National Library of Medicine. This database contains research studies from United States and other countries around the world. Our study has not been previously published. The ClinicalTrials.gov registration identifier is NCT04741750.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-08982-1","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T01:01:52Z","timestamp":1705626112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Stacey L.","family":"Klaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job G.","family":"Godino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney V.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letty","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ramers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"3","key":"8982_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.30297","volume":"69","author":"MG Hofmesiter","year":"2019","unstructured":"Hofmesiter MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, Edlin BR, Mermin J, Ward JW, Ryerson AB. Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016. Hepatology. 2019;69(3):1020\u201331.","journal-title":"Hepatology"},{"issue":"5","key":"8982_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","volume":"7","author":"EB Cunningham","year":"2022","unstructured":"Cunningham EB, Wheeler A, Hajarizadeh B, French CE, Roche R, Marshall AD. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(5):426\u201345. https:\/\/doi.org\/10.1016\/S2468-1253(21)00471-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"8982_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2468-1253(22)00346-6","volume":"8","author":"A Trickey","year":"2023","unstructured":"Trickey A, Fajardo E, Alemu D, Artenie AA, Easterbrook P. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(3):253\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(22)00346-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8982_CR4","unstructured":"Surveillance for Viral Hepatitis \u2013 United States, 2017. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2017surveillance\/index.htm. Accessed 26 Sept 2019."},{"key":"8982_CR5","unstructured":"New Hepatitis C Cases Rise for Seventh Year in a row. September 10, 2019 Press Release. AIDS Institute. http:\/\/www.theaidsinstitute.org\/sites\/default\/files\/attachments\/CDC%20hepatitis%20data%20press%20release.pdf. Accessed 26 Sept 2019."},{"issue":"6","key":"8982_CR6","doi-asserted-by":"publisher","first-page":"e0251635","DOI":"10.1371\/journal.pone.0251635","volume":"16","author":"A Wynn","year":"2021","unstructured":"Wynn A, Tweeten S, McDonald E, Wooten W, et al. The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018. PLoS One. 2021;16(6):e0251635. https:\/\/doi.org\/10.1371\/journal.pone.0251635.","journal-title":"PLoS One"},{"key":"8982_CR7","unstructured":"World Health Organization. Global Hepatitis Report 2017. https:\/\/www.who.int\/publications\/i\/item\/9789241565455\/. Accessed 26 Sept 2019."},{"key":"8982_CR8","unstructured":"World Health Organization, Global Hepatitis Programme. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. 2018. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531733\/. Accessed 5 Sept 2019."},{"key":"8982_CR9","unstructured":"Dietrich DT, Ahn J, Bacon B, Bernstein D, Bourliere M, Flamm S, Kwo P, Lim JK, Ramers CB, Reau N, Sulkowski M, Sussman N, Zeuzem S. A Simplified Algorithm for the Management of Hepatitis C Infection. Proceedings from a Consensus Meeting. September 2018. Gastroenterol Hepatol (NY). 2019;15 Suppl 3:1-12."},{"key":"8982_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","volume":"47","author":"BL Norton","year":"2017","unstructured":"Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196\u2013201. https:\/\/doi.org\/10.1016\/j.drugpo.2017.07.021.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"8982_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","volume":"7","author":"AH Litwin","year":"2022","unstructured":"Litwin AH, Lum PJ, Taylor LE, et al. Patient-centered models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2022;7(12):1112\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(22)00275-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"8982_CR12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/cid\/ciz696","volume":"70","author":"C Graf","year":"2020","unstructured":"Graf C, M\u00fccke MM, Dultz G, et al. Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(11):2355\u201365. https:\/\/doi.org\/10.1093\/cid\/ciz696.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"8982_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1370\/afm.2069","volume":"15","author":"KE Lasser","year":"2017","unstructured":"Lasser KE, Heinz A, Battisti L, et al. A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home. Ann Fam Med. 2017;15(3):258\u201361. https:\/\/doi.org\/10.1370\/afm.2069.","journal-title":"Ann Fam Med"},{"issue":"4","key":"8982_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40506-018-0177-5","volume":"10","author":"A Zuckerman","year":"2018","unstructured":"Zuckerman A, Carver A, Chastain CA. Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes. Curr Treat Options Infect Dis. 2018;10(4):431\u201346. https:\/\/doi.org\/10.1007\/s40506-018-0177-5.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"5","key":"8982_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/M17-0118","volume":"167","author":"S Kattakuzhy","year":"2017","unstructured":"Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial HCV Infection Treatment by Nonspecialist Providers (ASCEND). Ann Intern Med. 2017;167(5):311\u20138. https:\/\/doi.org\/10.7326\/M17-0118.","journal-title":"Ann Intern Med"},{"key":"8982_CR16","doi-asserted-by":"publisher","unstructured":"Pedlar A, Sandhu PJ. (2019). Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities. J Am Assoc Nurse Pract. 2020; 32(8):563-568. https:\/\/doi.org\/10.1097\/JXX.0000000000000269.","DOI":"10.1097\/JXX.0000000000000269"},{"issue":"5","key":"8982_CR17","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s10900-014-9932-9","volume":"39","author":"JP Morano","year":"2014","unstructured":"Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for Hepatitis C Testing and Linkage to Care for Vulnerable Populations: Point-of-Care and Standard HCV Testing in a Mobile Medical Clinic. J Community Health. 2014;39(5):922\u201334. https:\/\/doi.org\/10.1007\/s10900-014-9932-9.","journal-title":"J Community Health"},{"issue":"3","key":"8982_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, Cunningham EB, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(17)30404-1. (Epub 2018 Jan 6).","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"8982_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2019.10.010","volume":"72","author":"GJ Dore","year":"2020","unstructured":"Dore GJ, Feld JJ, Thompson A, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasyir, a randomized non-inferiority trial. J Hepatol. 2020;72(3):431\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.010. (Epub 2019 Oct 23).","journal-title":"J Hepatol"},{"key":"8982_CR20","unstructured":"Family Health Centers of San Diego electronic health record data for population aged 18 or older. 2020-2021."},{"key":"8982_CR21","unstructured":"Family Health Centers of San Diego electronic health record data for population aged 18 or older. 2021."},{"key":"8982_CR22","unstructured":"R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org\/. Accessed 26 Sept 2019."},{"key":"8982_CR23","unstructured":"StataCorp (2019). Stata Statistical Software: Release 16. StataCorp LLC, College Station, TX. https:\/\/www.stata.com."},{"issue":"3","key":"8982_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/1536867X130130030","volume":"13","author":"EC Norton","year":"2013","unstructured":"Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata J. 2013;13(3):492\u2013509. https:\/\/doi.org\/10.1177\/1536867X130130030.","journal-title":"Stata J"},{"issue":"1","key":"8982_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ijerph8010015","volume":"8","author":"J Efird","year":"2011","unstructured":"Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health. 2011;8(1):15\u201320. https:\/\/doi.org\/10.3390\/ijerph8010015.","journal-title":"Int J Environ Res Public Health."},{"key":"8982_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/9780470258019","volume-title":"Applied Survival Analysis: Regression Modeling of Time-to-Event Data","author":"DW Hosmer Jr","year":"2008","unstructured":"Hosmer DW Jr, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2008.","edition":"2"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-08982-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-08982-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-08982-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T01:02:13Z","timestamp":1705626133000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-08982-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8982"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-08982-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations, and present no more than minimal risk to patients. Informed consent will be obtained from all patients. All patients included in the study completed Family Health Centers of San Diego\u2019s Broad Consent, which includes a specific authorization for the use of de-identified health information for population health and quality improvement studies. Additional written consent will be obtained from patients enrolled in the study to be tested for HCV. Furthermore, verbal consent will be obtained from patients for group assignment. The study methods were reviewed and approved by the Institutional Review Board at San Diego State University, San Diego, California (HS-2022\u20130113).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/a.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}